Skip to main content
SpringerLink
Log in

Hyperprolaktinämie

Hyperprolactinaemia

  • CME Zertifizierte Fortbildung
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Wohl kaum ein in der Gynäkologie bedeutsames Hormon bereitet so häufig Probleme bei der Interpretation und ist daher ein möglicher Ausgangspunkt fragwürdiger diagnostischer und therapeutischer Entscheidungen wie Prolaktin. Nichtsdestotrotz kommt ihm im weiblichen Zyklus eine große Bedeutung zu. Unsicherheit besteht oft hinsichtlich der Notwendigkeit einer bildgebenden Diagnostik, dem Follow up auffälliger Werte, dem Verhalten bei Zyklusstörungen, bei Kinderwunsch, in der Schwangerschaft und Stillzeit. Diese Arbeit beschäftigt sich mit den genannten Punkten. Ihr Ziel ist: die Zusammenfassung der praxisrelevanten Kenntnisse und die Erarbeitung von Vorschlägen für mögliche Flussschemata in der Routine.

Abstract

Prolactin is an important hormone in the female menstrual cycle but it often leads to misinterpretation followed by sometimes questionable diagnostic and therapeutic decisions. Uncertainty often exists concerning the necessity for imaging procedures in the primary diagnostics and during the follow-up of increased serum prolactin levels, the procedure in patients with cycle irregularities, sterility, during pregnancy and lactation. The article deals with these problems, gives a summary of practically relevant knowledge and presents possible flow sheets for routine work.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Riddle O, Bates RW, Dykshorn SW (1933) The preparation, identification and assay of prolactin – a hormone of the anterior pituitary. Am J Physiol 105:191–216

    CAS  Google Scholar 

  2. Goffin V, Binart N, Touraine P, Kelly PA (2002) Prolactin. The new biology of an old hormone. Annu Rev Physiol 64:47–67

    Article  CAS  PubMed  Google Scholar 

  3. Goffin V, Shiverick KT, Kelly PA, Martial JA (1996) Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr Rev 17:385–410

    CAS  PubMed  Google Scholar 

  4. Yazigi RA, Quintero CH, Salameh WA (1997) Prolactin disorders. Fertil Steril 67:215–225

    Article  CAS  PubMed  Google Scholar 

  5. Jacobs LS, Snyder PJ, Wilbur JF et al (1971) Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man. J Clin Endocrinol Metab 33:996–998

    Article  CAS  PubMed  Google Scholar 

  6. Clemens JA, Roush ME, Fuller RW (1978) Evidence that serotonin neurons stimulate secretion of prolactin releasing factor. Life Sci 22:2209–2213

    Article  CAS  PubMed  Google Scholar 

  7. Maslar IA, Riddick DH (1979) Prolactin production by human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 135:751–754

    CAS  PubMed  Google Scholar 

  8. Ben-Jonathan N, Mershon JL, Allen DL et al (1996) Extrapituitary prolactin: distribution, regulation and clinical aspects. Endocr Rev 17:639–669

    CAS  PubMed  Google Scholar 

  9. McNatty KP, Sawers RS, McNeilly AS (1974) A possible role for prolactin in control of steroid secretion by the Graafian follicle. Nature 250:653–655

    Article  CAS  PubMed  Google Scholar 

  10. Phelps JY, Bugg EM, Shamblott MJ et al (2003) Prolactin gene expression in human ovarian follicular cells. Fertil Steril 79:182–185

    Article  PubMed  Google Scholar 

  11. Golander A, Hurley T, Barret J et al (1978) Prolactin synthesis by human chorion-decidual tissue: a possible source of prolactin in the amniotic fluid. Science 202:311–313

    Article  CAS  PubMed  Google Scholar 

  12. Sinha YN (1995) Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16:354–396

    Article  CAS  PubMed  Google Scholar 

  13. Posner BI, Kelly PA, Shiu RP, Friesen HG (1974) Studies of insulin, growth hormone and prolactin binding: tissue distribution, species variation and characterization. Endocrinology 95:521–531

    Article  CAS  PubMed  Google Scholar 

  14. Arden KC, Boutin JM, Djiane J et al (1990) The receptors for prolactin and growth hormone are localized in the same region of human chromosome 5. Cytogenet Cell Genet 53:161–165

    Article  CAS  PubMed  Google Scholar 

  15. Astwood EB (1941) The regulation of corpus luteum function by hypophysial luteotrophin. Endocrinology 29:309–319

    Article  Google Scholar 

  16. Bole-Feysot C, Goffin V, Edery M et al (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225–268

    Article  CAS  PubMed  Google Scholar 

  17. Raber W, Gessl A, Nowotny P, Vierhapper H (2003) Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization. Clin Endocrinol (Oxf) 58:185–191

    Google Scholar 

  18. Schlechte J, Dolan K, Sherman B et al (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412–418

    Article  CAS  PubMed  Google Scholar 

  19. Verhelst J, Abs R (2003) Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2:23–32

    Article  PubMed  Google Scholar 

  20. Nawroth F (2005) Hyperprolactinemia and the regular menstrual cycle in asymptomatic women – should it be treated during therapy of infertility? Reprod Biomed Online 11:581–588

    Article  CAS  PubMed  Google Scholar 

  21. Velasquez EV, Trigo RV, Creus S et al (2006) Pituitary-ovarian axis during lactational amenorrhoea. I. Longitudinal assessment of follicular growth, gonadotrophins, sex steroids and inhibin levels before and after recovery of menstrual cyclicity. Hum Reprod 21:909–915

    Article  CAS  PubMed  Google Scholar 

  22. Velasquez EV, Creus S, Trigo RV et al (2006) Pituitary-ovarian axis during lactational amenorrhoea. II. Longitudinal assessment of serum FSH polymorphism before and after recovery of menstrual cycles. Hum Reprod 21:916–923

    Article  CAS  PubMed  Google Scholar 

  23. Naliato EC, Violante AH, Caldas D et al (2008) Bone density in women with prolactinoma treated with dopamine agonists. Pituitary 11:21–28

    Article  CAS  PubMed  Google Scholar 

  24. Vartej P, Poiana C, Vartej I (2001) Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women. Gynecol Endocrinol 15:43–47

    Article  CAS  PubMed  Google Scholar 

  25. Ono M, Miki N, Amano K et al (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95:2672–2679

    Article  CAS  PubMed  Google Scholar 

  26. Nawroth F, Ludwig M (2007) Persistierende Hyperprolaktinämie ohne Zyklusstörungen. Frauenarzt 48:454–459

    Google Scholar 

  27. Molitch ME, Russell EJ (1990) The pituitary „incidentaloma“. Ann Intern Med 112:925–931

    Article  CAS  PubMed  Google Scholar 

  28. Barlier A, Jaquet P (2006) Quinagolide – a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol 154:187–195

    Article  CAS  PubMed  Google Scholar 

  29. Schade R, Andersohn F, Suissa S et al (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38

    Article  CAS  PubMed  Google Scholar 

  30. Zanettini R, Antonini A, Gatto G et al (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46

    Article  CAS  PubMed  Google Scholar 

  31. Tan T, Cabrita IZ, Hensman D et al (2010) Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf) 73:369–374

    Google Scholar 

  32. Auriemma RS, Pivonello R, Perone Y et al (2013) Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol 169:359–366

    Article  CAS  PubMed  Google Scholar 

  33. Dekkers OM, Lagro J, Burman P et al (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95:43–51

    Article  CAS  PubMed  Google Scholar 

  34. Colao A, Di Sarno A, Cappabianca P et al (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033

    Article  CAS  PubMed  Google Scholar 

  35. Auriemma RS, Perone Y, Di Sarno A et al (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98:372–379

    Article  CAS  PubMed  Google Scholar 

  36. Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. F. Nawroth gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Facharzt-Zentrum für Kinderwunsch, Pränatale Medizin, Endokrinologie und Osteologie, amedes experts Hamburg, Mönckebergstr. 10 (Barkhof), 20095, Hamburg, Deutschland

    F. Nawroth

Authors
  1. F. Nawroth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Nawroth.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nawroth, F. Hyperprolaktinämie. Gynäkologe 48, 383–393 (2015). https://doi.org/10.1007/s00129-014-3509-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-014-3509-7

Schlüsselwörter

Keywords

Search

Navigation